PYXS Pyxis Oncology1.52-1.85 (-54.9%)
Premarket Decliner
PYXS Pyxis Oncology3.37-0.63-15.8%
Premarket:1.99-1.38 (-41.0%)
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Globe NewswireThu, 18-Dec 7:00 AM
PYXS Pyxis Oncology5.39+0.05 (+0.9%)
PYXS Pyxis Oncology5.32+0.17 (+3.3%)
PYXS Pyxis Oncology3.34+0.43 (+14.8%)
PYXS Pyxis Oncology2.03-1.79 (-46.9%)